Skip to content
TrialScanner

NCT04068753

Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

Phase 2Active, not recruitingGSKCollaborator

Registry record

Lead sponsor
University of Oklahoma
Conditions
Recurrent Cervix Cancer; Progressive Cervix Cancer
Primary completion
Aug 6, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04068753 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

2 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04068753: Niraparib in Combination... | TrialScanner